Small Molecules

28 Oct 2019 First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes: Takeda's Investigational Therapy Meets Co-Primary & Key Secondary Efficacy Endpoints
28 Oct 2019 Microbion Corporation Announces Results from Randomized, Double Blind, Placebo-Controlled Phase 1b Trial of Pravibismane (MBN-101) for Treatment of Moderate to Severe Chronic Infected Diabetic Foot Ulcers
28 Oct 2019 ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at AACR-NCI-EORTC Annual Conference
28 Oct 2019 Deciphera Pharmaceuticals Presents Data from Rebastinib and DCC-3116 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
28 Oct 2019 Mirum Pharmaceuticals Announces Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome
26 Oct 2019 LIPAC Oncology Announces Successful Completion of Phase 1 Bladder Cancer Clinical Study and Initiation of Phase 2A Study
25 Oct 2019 Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
25 Oct 2019 European Commission Approves Astellas' XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
25 Oct 2019 Syros Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newly Diagnosed Unfit AML Patients
25 Oct 2019 GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
24 Oct 2019 GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
23 Oct 2019 Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC Targeted Protein Degraders
23 Oct 2019 RAPT Therapeutics Announces Initiation of First-in-Human Phase 1 Study of RPT193
23 Oct 2019 Oligomerix Presents Preclinical Data on Lead Alzheimer’s Disease Candidate at Neuroscience 2019
23 Oct 2019 Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1 Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo
22 Oct 2019 Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease
22 Oct 2019 Trovagene Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer
22 Oct 2019 Cerevel Therapeutics Initiates Phase 1b Clinical Trial of CVL-231, a M4 Selective Positive Allosteric Modulator in Development for the Treatment of Schizophrenia
22 Oct 2019 ABIVAX Reports Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study at United European Gastroenterology Conference
22 Oct 2019 FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation
21 Oct 2019 Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
21 Oct 2019 Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965
21 Oct 2019 Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer
21 Oct 2019 Farxiga approved in the US to reduce the risk of hospitalisation for heart failure in patients with type-2 diabetes
21 Oct 2019 Daiichi Sankyo Receives Negative CHMP Opinion for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/ Refractory FLT3-ITD AML

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up